We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Functional influence of botulinum neurotoxin type A treatment (Xeomin(R)) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.

Clinical and functional measurements before, 1 week, and 1 month after Xeomin® administration. A) Spasticity (Modified Ashworth Scale [MAS]); B) Pain (visual analog scale [VAS]); C) Trunk control capacity (TCT); D) Motricity index (MI); E) Visual gait analysis scores (VGA); F) Gait velocity. Numbers given are mean values, with error bars representing standard deviation of three measurements. Open and closed bars represent upper and lower limbs, respectively; hatched bars are used for tests not performed in limbs.

Maurizio Falso, et al. Neurol Int. 2012 June 14;4(2):e8.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk